HZ-L105

N/A

Report date: 2025/03/31 10:53:17
NME

Base Information

Drug NameHZ-L105
Drug Alias NameHZ-L105
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionApoptosis regulator Bcl-2 inhibitors
TargetsApoptosis regulator Bcl-2
Therapy Area/IndicationsHematologic NeoplasmsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHeaZen Therapeutics Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesBiopolar Hongye (Nantong) Pharmaceutical Co LtdHeaZen Therapeutics Co Ltd
Inactive CompaniesN/A
Active IndicationsHematologic NeoplasmsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A